Company logo

LGVN - Longeveron Inc.

NASDAQ -> Healthcare -> Biotechnology
Miami, United States

LGVN price evolution
LGVN
(in millions $) 30 Oct 2021 30 Jul 2021 30 Apr 2021 30 Jan 2021
Current assets
Cash $9.74 $16.83 $24.46 $0.82
Short term investments
Net receivables $0.17 $0.13 $0.42
Inventory
Total current assets $19.66 $22.11 $25.3 $1.85
Long term investments
Property, plant & equipment $3.07 $3.23 $3.42 $3.6
Goodwill & intangible assets
Total noncurrent assets $7.49 $7.75 $7.13 $7.39
Total investments
Total assets $27.15 $29.86 $32.43 $9.24
Current liabilities
Accounts payable $0.36 $0.15 $0.9 $1.59
Deferred revenue $0.2 $0.23 $0.39 $0.01
Short long term debt
Total current liabilities $1.93 $2.19 $2.78 $3.83
Long term debt $0.14 $0.14 $0.15 $0.31
Total noncurrent liabilities $2.88 $3.02 $3.16 $3.45
Total debt
Total liabilities $4.82 $5.21 $5.94 $7.28
Shareholders' equity
Retained earnings -$39.87 -$35.01 -$30
Other shareholder equity -$0.1 -$0.1 -$0.1 $1.96
Total shareholder equity
(in millions $) 30 Jan 2021 30 Jan 2020
Current assets
Cash $0.82 $1.87
Short term investments
Net receivables $0.42 $0.45
Inventory
Total current assets $1.85 $2.37
Long term investments
Property, plant & equipment $3.6 $4.19
Goodwill & intangible assets
Total noncurrent assets $7.39 $8.21
Total investments
Total assets $9.24 $10.58
Current liabilities
Accounts payable $1.59 $1.15
Deferred revenue $0.01 $0.54
Short long term debt
Total current liabilities $3.83 $2.49
Long term debt $0.31
Total noncurrent liabilities $3.45 $3.65
Total debt
Total liabilities $7.28 $6.14
Shareholders' equity
Retained earnings
Other shareholder equity $1.96 $4.45
Total shareholder equity
(in millions $) 30 Oct 2021 30 Jul 2021 30 Apr 2021 30 Jan 2021
Revenue
Total revenue $0.23 $0.49 $0.38
Cost of revenue
Gross Profit $0.16 $0.21 $0.15
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $5.14 $5.55 $3.83
Operating income -$4.91 -$5.06 -$3.46
Income from continuing operations
EBIT
Income tax expense
Interest expense $0 $0
Net income
Net income -$4.86 -$5.01 -$3.11
Income (for common shares)
(in millions $) 30 Jan 2021 30 Jan 2020
Revenue
Total revenue $5.63 $5.64
Cost of revenue
Gross Profit $1.83 $1.75
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $6.41 $5.64
Operating income -$3.78 -$3
Income from continuing operations
EBIT
Income tax expense
Interest expense $0.01 $0
Net income
Net income -$3.72 -$2.96
Income (for common shares)
(in millions $) 30 Oct 2021 30 Jul 2021 30 Apr 2021 30 Jan 2021
Net income -$12.98 -$8.12 -$3.11 -$3.72
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$8.36 -$5.98 -$3.03 -$2.36
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$9.38 -$4.66 -$0.26
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $26.66 $26.66 $26.68 $1.57
Effect of exchange rate
Change in cash and equivalents $8.92 $16.02 $23.64 -$1.05
(in millions $) 30 Jan 2021 30 Jan 2020
Net income -$3.72 -$2.96
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations -$2.36 -$2.39
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.26 -$0.13
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $1.58 $0.35
Effect of exchange rate
Change in cash and equivalents -$1.05 -$2.17
Fundamentals
Market cap $384.71M
Enterprise value N/A
Shares outstanding 19.12M
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share 0.51
EPS N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 10.18
Quick ratio N/A